Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: A preliminary report

Bipolar Disorders

Volumn 16, Issue 4, 2014, Pages 432-440

  Reininghaus, Eva Z ^a   Mcintyre, Roger S ^b,c   Reininghaus, Bernd ^a   Geisler, Simon ^d   Bengesser, Susanne A ^a   Lackner, Nina ^a   Hecht, Karen ^a   Birner, Armin ^a   Kattnig, Fabian ^a,e   Unterweger, Renate ^a   Kapfhammer, Hans Peter ^a   Zelzer, Sieglinde ^a   Fuchs, Dietmar ^d   Mangge, Harald ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY OF GRAZ   (Austria)

Author keywords

Bipolar disorder; IDO; Immune system; Inflammation; Neopterin; Obesity; Overweight; T cells; Tryptophan

Indexed keywords

KYNURENINE; NEOPTERIN; TRYPTOPHAN;

ADULT; ARTICLE; BIPOLAR DISORDER; BODY MASS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HOMEOSTASIS; HUMAN; MAJOR CLINICAL STUDY; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; BLOOD; COMPLICATION; FEMALE; MALE; MIDDLE AGED; OVERWEIGHT;

ADULT; BIPOLAR DISORDER; FEMALE; HUMANS; KYNURENINE; MALE; MIDDLE AGED; OVERWEIGHT; TRYPTOPHAN;

EID: 84901847279     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12166     Document Type: Article

References (73)

1. McIntyre RS, Danilewitz M, Liauw SS et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord 2010; 126: 366-387.
2. Fagiolini A, Frank E, Houck PR et al. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry 2002; 63: 528-533.
3. Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005; 7: 424-430.
4. Fagiolini A, Kupfer DJ, Houck PR, Novick DM, Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am J Psychiatry 2003; 160: 112-117.
5. Fagiolini A, Kupfer DJ, Rucci P, Scott JA, Novick DM, Frank E. Suicide attempts and ideation in patients with bipolar I disorder. J Clin Psychiatry 2004; 65: 509-514.
6. Bond DJ, Lang DJ, Noronha MM et al. The association of elevated body mass index with reduced brain volumes in first-episode mania. Biol Psychiatry 2011; 70: 381-387.
7. Maina G, Salvi V, Vitalucci A, D'Ambrosio V, Bogetto F. Prevalence and correlates of overweight in drug-naive patients with bipolar disorder. J Affect Disord 2008; 110: 149-155.
8. Yim CY, Soczynska JK, Kennedy SH, Woldeyohannes HO, Brietzke E, McIntyre RS. The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. Eur Psychiatry 2012; 27: 223-228.
9. Wang PW, Sachs GS, Zarate CA et al. Overweight and obesity in bipolar disorders. J Psychiatr Res 2006; 40: 762-764.
10. Goldstein BI, Liu SM, Schaffer A, Sala R, Blanco C. Obesity and the three-year longitudinal course of bipolar disorder. Bipolar Disord 2013; 15: 284-293.
11. Angst J, Hengartner MP, Gamma A, von Zerssen D, Angst F. Mortality of 403 patients with mood disorders 48 to 52 years after their psychiatric hospitalisation. Eur Arch Psychiatry Clin Neurosci 2013; 263: 425-434.
12. Kintscher U, Hartge M, Hess K et al. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 2008; 28: 1304-1310.
13. Nishimura S, Manabe I, Nagai R. Adipose tissue inflammation in obesity and metabolic syndrome. Discov Med 2009; 8: 55-60.
14. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010; 72: 219-246.
15. Toni R, Malaguti A, Castorina S, Roti E, Lechan RM. New paradigms in neuroendocrinology: relationships between obesity, systemic inflammation and the neuroendocrine system. J Endocrinol Invest 2004; 27: 182-186.
16. Wirleitner B, Neurauter G, Schrocksnadel K, Frick B, Fuchs D. Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 2003; 10: 1581-1591.
17. Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy States. Int J Tryptophan Res 2009; 2: 1-19.
18. Myint AM. Kynurenines: from the perspective of major psychiatric disorders. FEBS J 2012; 279: 1375-1385.
19. Carlin JM, Ozaki Y, Byrne GI, Brown RR, Borden EC. Interferons and indoleamine 2, 3-dioxygenase: role in antimicrobial and antitumor effects. Experientia 1989; 45: 535-541.
20. Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2, 3-dioxygenase, and tryptophan catabolism. FASEB J 1991; 5: 2516-2522.
21. Hu B, Hissong BD, Carlin JM. Interleukin-1 enhances indoleamine 2, 3-dioxygenase activity by increasing specific mRNA expression in human mononuclear phagocytes. J Interferon Cytokine Res 1995; 15: 617-624.
22. Musso T, Gusella GL, Brooks A, Longo DL, Varesio L. Interleukin-4 inhibits indoleamine 2, 3-dioxygenase expression in human monocytes. Blood 1994; 83: 1408-1411.
23. Fuchs D, Moller AA, Reibnegger G, Stockle E, Werner ER, Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr 1990; 3: 873-876.
24. Bearden CE, Hoffman KM, Cannon TD. The neuropsychology and neuroanatomy of bipolar affective disorder: a critical review. Bipolar Disord 2001; 3: 106-150; discussion 151-153.
25. Malhi GS, Ivanovski B, Hadzi-Pavlovic D, Mitchell PB, Vieta E, Sachdev P. Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord 2007; 9: 114-125.
26. Martínez-Arán A, Vieta E, Colom F et al. Cognitive impairment in euthymic bipolar patients: implications for clinical and functional outcome. Bipolar Disord 2004; 6: 224-232.
27. Martinez-Aran A, Vieta E, Colom F et al. Cognitive dysfunctions in bipolar disorder: evidence of neuropsychological disturbances. Psychother Psychosom 2000; 69: 2-18.
28. Robinson LJ, Thompson JM, Gallagher P et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord 2006; 93: 105-115.
29. Sole B, Bonnin CM, Torrent C et al. Neurocognitive impairment and psychosocial functioning in bipolar II disorder. Acta Psychiatr Scand 2012; 125: 309-317.
30. Thompson JM, Gallagher P, Hughes JH et al. Neurocognitive impairment in euthymic patients with bipolar affective disorder. Br J Psychiatry 2005; 186: 32-40.
31. Brook JS, Zhang C, Saar NS, Brook DW. Psychosocial predictors, higher body mass index, and aspects of neurocognitive dysfunction. Percept Mot Skills 2009; 108: 181-195.
32. Cohen RA. Obesity-associated cognitive decline: excess weight affects more than the waistline. Neuroepidemiology 2010; 34: 230-231.
33. Cournot M, Marquie JC, Ansiau D et al. Relation between body mass index and cognitive function in healthy middle-aged men and women. Neurology 2006; 67: 1208-1214.
34. Elias MF, Elias PK, Sullivan LM, Wolf PA, D'Agostino RB. Obesity, diabetes and cognitive deficit: the Framingham Heart Study. Neurobiol Aging 2005; 26 (Suppl. 1): 11-16.
35. Fergenbaum JH, Bruce S, Lou W, Hanley AJ, Greenwood C, Young TK. Obesity and lowered cognitive performance in a Canadian First Nations population. Obesity 2009; 17: 1957-1963.
36. Gunstad J, Paul RH, Cohen RA, Tate DF, Spitznagel MB, Gordon E. Elevated body mass index is associated with executive dysfunction in otherwise healthy adults. Compr Psychiatry 2007; 48: 57-61.
37. Jeong SK, Nam HS, Son MH, Son EJ, Cho KH. Interactive effect of obesity indexes on cognition. Dement Geriatr Cogn Disord 2005; 19: 91-96.
38. McIntyre RS, Kenna HA, Nguyen HT et al. Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders? Adv Ther 2010; 27: 63-80.
39. Nilsson LG, Nilsson E. Overweight and cognition. Scand J Psychol 2009; 50: 660-667.
40. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ 2005; 330: 1360.
41. Xu WL, Atti AR, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Midlife overweight and obesity increase late-life dementia risk: a population-based twin study. Neurology 2011; 76: 1568-1574.
42. Drexhage RC, Hoogenboezem TH, Versnel MA, Berghout A, Nolen WA, Drexhage HA. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav Immun 2011; 25: 1206-1213.
43. Soczynska JK, Kennedy SH, Woldeyohannes HO et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromolecular Med 2011; 13: 93-116.
44. Berk M, Kapczinski F, Andreazza AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804-817.
45. Kennett GA, Joseph MH. The functional importance of increased brain tryptophan in the serotonergic response to restraint stress. Neuropharmacology 1981; 20: 39-43.
46. Raison CL, Dantzer R, Kelley KW et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010; 15: 393-403.
47. Miura H, Ando Y, Noda Y, Isobe K, Ozaki N. Long-lasting effects of inescapable-predator stress on brain tryptophan metabolism and the behavior of juvenile mice. Stress 2011; 14: 262-272.
48. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm 2000; 107: 343-353.
49. Gulaj E, Pawlak K, Bien B, Pawlak D. Kynurenine and its metabolites in Alzheimer's disease patients. Adv Med Sci 2010; 55: 204-211.
50. Gold AB, Herrmann N, Swardfager W et al. The relationship between indoleamine 2, 3-dioxygenase activity and post-stroke cognitive impairment. J Neuroinflammation 2011; 8: 17.
51. Kapczinski F, Dias VV, Kauer-Sant'Anna M et al. Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother 2009; 9: 957-966.
52. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 1997; 43: 2424-2426.
53. Bühner M, Ziegel M. Statistik Für Psychologen Und Sozialwissenschaftler (Pearson Studium - Psychologie). München: Pearson Education, 2009.
54. Langan C, McDonald C. Neurobiological trait abnormalities in bipolar disorder. Mol Psychiatry 2009; 14: 833-846.
55. Brandacher G, Hoeller E, Fuchs D, Weiss HG. Chronic immune activation underlies morbid obesity: is IDO a key player? Curr Drug Metab 2007; 8: 289-295.
56. Myint AM, Kim YK, Verkerk R et al. Tryptophan breakdown pathway in bipolar mania. J Affect Disord 2007; 102: 65-72.
57. Breunis MN, Kupka RW, Nolen WA et al. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol Psychiatry 2003; 53: 157-165.
58. Nathan CF, Murray HW, Wiebe ME, Rubin BY. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983; 158: 670-689.
59. Stelzer I, Zelzer S, Raggam RB et al. Link between leptin and interleukin-6 levels in the initial phase of obesity related inflammation. Transl Res 2012; 159: 118-124.
60. Brandacher G, Winkler C, Aigner F et al. Bariatric surgery cannot prevent tryptophan depletion due to chronic immune activation in morbidly obese patients. Obes Surg 2006; 16: 541-548.
61. Wolowczuk I, Hennart B, Leloire A et al. Tryptophan metabolism activation by indoleamine 2, 3-dioxygenase in adipose tissue of obese women: an attempt to maintain immune homeostasis and vascular tone. Am J Physiol Regul Integr Comp Physiol 2012; 303: R135-R143.
62. O'Connor JC, Lawson MA, Andre C et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2, 3-dioxygenase activation in mice. Mol Psychiatry 2009; 14: 511-522.
63. Oxenkrug GF. Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan-kynurenine metabolism. Ann N Y Acad Sci 2010; 1199: 1-14.
64. Winkler C, Frick B, Schroecksnadel K, Schennach H, Fuchs D. Food preservatives sodium sulfite and sorbic acid suppress mitogen-stimulated peripheral blood mononuclear cells. Food Chem Toxicol 2006; 44: 2003-2007.
65. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab 2002; 3: 175-187.
66. Weiss G, Fuchs D, Hausen A et al. Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett 1993; 321: 89-92.
67. Grammer TB, Fuchs D, Boehm BO, Winkelmann BR, Maerz W. Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 2009; 55: 1135-1146.
68. Ray KK, Morrow DA, Sabatine MS et al. Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome. Circulation 2007; 115: 3071-3078.
69. Vengen IT, Dale AC, Wiseth R, Midthjell K, Videm V. Neopterin predicts the risk for fatal ischemic heart disease in type 2 diabetes mellitus: long-term follow-up of the HUNT 1 study. Atherosclerosis 2009; 207: 239-244.
70. Neurauter G, Schrocksnadel K, Scholl-Burgi S et al. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab 2008; 9: 622-627.
71. Hoekstra R, Fekkes D, Pepplinkhuizen L, Loonen AJ, Tuinier S, Verhoeven WM. Nitric oxide and neopterin in bipolar affective disorder. Neuropsychobiology 2006; 54: 75-81.
72. Blasko I, Knaus G, Weiss E et al. Cognitive deterioration in Alzheimer's disease is accompanied by increase of plasma neopterin. J Psychiatr Res 2007; 41: 694-701.
73. Felger JC, Li L, Marvar PJ et al. Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations. Brain Behav Immun 2013; 31: 153-160.